Mairinger Severin, Kwon Mihye, Bauer Martin, Song Jinho, Lackner Edith, Jorda Anselm, Bergmann Felix, Minichmayr Iris K, Kim Ka Yeon, Choi Min Sun, Shim Jae Hoon, Dueker Stephen R, Zeitlinger Markus, Langer Oliver
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.
Korea Radio-Isotope Center for Pharmaceuticals, Korea Institute of Radiological & Medical Sciences, Seoul, Republic of Korea.
Drug Metab Dispos. 2025 Jul;53(7):100091. doi: 10.1016/j.dmd.2025.100091. Epub 2025 May 8.
An important safety consideration for topically administered drugs is the extent of systemic exposure they achieve. The aim of this study was to evaluate whether a topically administered microdose of the model drug diclofenac can predict the systemic availability, plasma, and tissue pharmacokinetics of a topical therapeutic dose. Eight healthy participants (6 men and 2 women) participated in a 4-period, crossover study. In period 1, a topical microdose (62 ± 6 μg) was administered; in period 2, a single intravenous microdose (0.95 ± 0.03 μg) was administered; in period 3, a topical therapeutic dose (120 mg) was administered; and in period 4, a single intravenous therapeutic dose (75 mg) of [C]diclofenac was administered, with or without the addition of unlabeled diclofenac. Venous blood, urine, and microdialysis samples from subcutaneous adipose tissue beneath the dermal application site were collected for 24 h post-dosing. Total C-concentrations in plasma and microdialysates were quantified using accelerator mass spectrometry. The disposition of intravenously administered [C]diclofenac was dose-linear. However, after topical administration, the fraction of total C absorbed (geometric mean and 95% confidence interval) was higher (P = .0019, 2-tailed, paired t test) for the microdose (0.48% and 0.34%-0.67%) compared with the therapeutic dose (0.13% and 0.07%-0.22%) (geometric mean ratio and 90% confidence interval: 3.79 and 2.41-5.98). Dose-normalized C-concentrations in microdialysates were low, variable, and did not differ between doses. Our study demonstrates the feasibility of quantifying C-concentrations in plasma and microdialysates following the topical administration of a microdose of [C]diclofenac. The observed nonlinearity in systemic availability after topical dosing suggests that microdosing may not accurately predict the disposition of certain topical drugs at therapeutic doses. SIGNIFICANCE STATEMENT: We assessed whether a topically applied microdose of diclofenac could predict the systemic availability of a therapeutic dose. Results showed that systemic absorption was not dose-linear, indicating that microdosing may have limited use for predicting the pharmacokinetics of some topical drugs.
局部给药药物的一个重要安全性考量是其全身暴露程度。本研究的目的是评估局部给予模型药物双氯芬酸的微量剂量是否能够预测局部治疗剂量的全身可用性、血浆及组织药代动力学。八名健康参与者(6名男性和2名女性)参与了一项为期4个阶段的交叉研究。在第1阶段,给予局部微量剂量(62±6μg);在第2阶段,给予单次静脉微量剂量(0.95±0.03μg);在第3阶段,给予局部治疗剂量(120mg);在第4阶段,给予单次静脉治疗剂量(75mg)的[C]双氯芬酸,添加或不添加未标记的双氯芬酸。给药后24小时收集静脉血、尿液以及来自皮肤应用部位下方皮下脂肪组织的微透析样本。使用加速器质谱法定量血浆和微透析液中的总C浓度。静脉注射[C]双氯芬酸的处置呈剂量线性。然而,局部给药后,微量剂量(几何平均值和95%置信区间)的总C吸收分数(0.48%和0.34%-0.67%)高于治疗剂量(0.13%和0.07%-0.22%)(P = 0.0019,双侧,配对t检验)(几何平均比值和90%置信区间:3.79和2.41-5.98)。微透析液中剂量标准化的C浓度较低且变化不定,不同剂量之间无差异。我们的研究证明了在局部给予微量剂量的[C]双氯芬酸后定量血浆和微透析液中C浓度的可行性。局部给药后全身可用性中观察到的非线性表明微量给药可能无法准确预测某些局部药物在治疗剂量下的处置情况。意义声明:我们评估了局部应用微量双氯芬酸是否能够预测治疗剂量的全身可用性。结果表明全身吸收并非剂量线性,这表明微量给药在预测某些局部药物的药代动力学方面可能用途有限。